What is it about?
Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study.
Featured Image
Photo by Ayo Ogunseinde on Unsplash
Why is it important?
PD may dramatically affect sexual function as well as quality of life. Despite the numerous treatment options, a standard and worldwide accepted consensus for the medical treatment of PD has yet to be identified. Many oral medicines have been reported as having limited success in treating PD. These treatment options include vitamin E, potassium aminobenzoate, tamoxifen, colchicines, orgotein, procarbazine, systemic steroids and nonspecific antihistamines. Intralesional therapy for PD includes injection of steroids, calcium channel blocker, interferons, purified clostridial collagenase, parathyroid hormone and orgotein. Local therapies include ultrasound, shortwave diathermy, laser therapy, iontophoresis and extracorporeal shock wave therapy.
Perspectives
Read the Original
This page is a summary of: Comparison of Vitamin E and Propionyl-L-Carnitine, Separately or in Combination, in Patients With Early Chronic Peyronie’s Disease: A Double-Blind, Placebo Controlled, Randomized Study, The Journal of Urology, October 2007, Wolters Kluwer Health,
DOI: 10.1016/j.juro.2007.05.162.
You can read the full text:
Resources
Contributors
The following have contributed to this page